PortalPublikationenSingle-course bleomycin, etoposide, and cisplatin (1xBEP) as...

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study

Standard

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. / Dieckmann, Klaus-Peter; Pokrivcak, Tomas; Geczi, Lajos; Niehaus, David; Dralle-Filiz, Inken; Matthies, Cord; Dienes, Tamas; Zschäbitz, Stefanie; Paffenholz, Pia; Gschliesser, Tanja; Pichler, Renate; Mego, Michal; Bader, Pia; Zengerling, Friedemann; Heinzelbecker, Julia; Krausewitz, Philipp; Krege, Susanne; Aurilio, Gaetano; Aksoy, Cem; Hentrich, Marcus; Seidel, Christoph; Törzsök, Péter; Nestler, Tim; Majewski, Matthaeus; Hiester, Andreas; Buchler, Tomas; Vallet, Sonia; Studentova, Hana; Schönburg, Sandra; Niedersüß-Beke, Dora; Ring, Julia; Trenti, Emanuela; Heidenreich, Axel; Wülfing, Christian; Isbarn, Hendrik; Pichlmeier, Uwe; Pichler, Martin.

in: THER ADV MED ONCOL, Jahrgang 14, 2022, S. 17588359221086813.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Dieckmann, K-P, Pokrivcak, T, Geczi, L, Niehaus, D, Dralle-Filiz, I, Matthies, C, Dienes, T, Zschäbitz, S, Paffenholz, P, Gschliesser, T, Pichler, R, Mego, M, Bader, P, Zengerling, F, Heinzelbecker, J, Krausewitz, P, Krege, S, Aurilio, G, Aksoy, C, Hentrich, M, Seidel, C, Törzsök, P, Nestler, T, Majewski, M, Hiester, A, Buchler, T, Vallet, S, Studentova, H, Schönburg, S, Niedersüß-Beke, D, Ring, J, Trenti, E, Heidenreich, A, Wülfing, C, Isbarn, H, Pichlmeier, U & Pichler, M 2022, 'Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study', THER ADV MED ONCOL, Jg. 14, S. 17588359221086813. https://doi.org/10.1177/17588359221086813

APA

Dieckmann, K-P., Pokrivcak, T., Geczi, L., Niehaus, D., Dralle-Filiz, I., Matthies, C., Dienes, T., Zschäbitz, S., Paffenholz, P., Gschliesser, T., Pichler, R., Mego, M., Bader, P., Zengerling, F., Heinzelbecker, J., Krausewitz, P., Krege, S., Aurilio, G., Aksoy, C., ... Pichler, M. (2022). Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. THER ADV MED ONCOL, 14, 17588359221086813. https://doi.org/10.1177/17588359221086813

Vancouver

Dieckmann K-P, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C et al. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. THER ADV MED ONCOL. 2022;14:17588359221086813. https://doi.org/10.1177/17588359221086813

Bibtex

@article{34711c37e7e6414dae1cf9ea8cb7a42c,
title = "Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study",
abstract = "Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population.Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively.Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate.Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.",
author = "Klaus-Peter Dieckmann and Tomas Pokrivcak and Lajos Geczi and David Niehaus and Inken Dralle-Filiz and Cord Matthies and Tamas Dienes and Stefanie Zsch{\"a}bitz and Pia Paffenholz and Tanja Gschliesser and Renate Pichler and Michal Mego and Pia Bader and Friedemann Zengerling and Julia Heinzelbecker and Philipp Krausewitz and Susanne Krege and Gaetano Aurilio and Cem Aksoy and Marcus Hentrich and Christoph Seidel and P{\'e}ter T{\"o}rzs{\"o}k and Tim Nestler and Matthaeus Majewski and Andreas Hiester and Tomas Buchler and Sonia Vallet and Hana Studentova and Sandra Sch{\"o}nburg and Dora Nieders{\"u}{\ss}-Beke and Julia Ring and Emanuela Trenti and Axel Heidenreich and Christian W{\"u}lfing and Hendrik Isbarn and Uwe Pichlmeier and Martin Pichler",
note = "{\textcopyright} The Author(s), 2022.",
year = "2022",
doi = "10.1177/17588359221086813",
language = "English",
volume = "14",
pages = "17588359221086813",
journal = "THER ADV MED ONCOL",
issn = "1758-8340",
publisher = "Old City Publishing",

}

RIS

TY - JOUR

T1 - Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study

AU - Dieckmann, Klaus-Peter

AU - Pokrivcak, Tomas

AU - Geczi, Lajos

AU - Niehaus, David

AU - Dralle-Filiz, Inken

AU - Matthies, Cord

AU - Dienes, Tamas

AU - Zschäbitz, Stefanie

AU - Paffenholz, Pia

AU - Gschliesser, Tanja

AU - Pichler, Renate

AU - Mego, Michal

AU - Bader, Pia

AU - Zengerling, Friedemann

AU - Heinzelbecker, Julia

AU - Krausewitz, Philipp

AU - Krege, Susanne

AU - Aurilio, Gaetano

AU - Aksoy, Cem

AU - Hentrich, Marcus

AU - Seidel, Christoph

AU - Törzsök, Péter

AU - Nestler, Tim

AU - Majewski, Matthaeus

AU - Hiester, Andreas

AU - Buchler, Tomas

AU - Vallet, Sonia

AU - Studentova, Hana

AU - Schönburg, Sandra

AU - Niedersüß-Beke, Dora

AU - Ring, Julia

AU - Trenti, Emanuela

AU - Heidenreich, Axel

AU - Wülfing, Christian

AU - Isbarn, Hendrik

AU - Pichlmeier, Uwe

AU - Pichler, Martin

N1 - © The Author(s), 2022.

PY - 2022

Y1 - 2022

N2 - Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population.Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively.Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate.Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.

AB - Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. We analyzed the outcome in a real-life population.Patients and Methods: In a multicentric international study, 423 NS CS1 patients receiving 1xBEP were retrospectively evaluated. Median follow-up was 37 (range, 6-89) months. Primary end points were relapse-free and overall survival evaluated after 5 years. We also looked at associations of relapse with clinico-pathological factors using stratified Kaplan-Meier methods and Cox regression models. Treatment modality and outcome of recurrences were analyzed descriptively.Results: The 5-year relapse-free survival rate was 96.2%. Thirteen patients (3.1%; 95% confidence interval, 1.65-5.04%) relapsed after a median time of 13 months, of which 10 were salvaged (77%). Relapses were mostly confined to retroperitoneal nodes. Three patients succumbed, two to disease progression and one to toxicity of chemotherapy. Pathological stage >pT2 was significantly associated with relapse rate.Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.

U2 - 10.1177/17588359221086813

DO - 10.1177/17588359221086813

M3 - SCORING: Journal article

C2 - 35386956

VL - 14

SP - 17588359221086813

JO - THER ADV MED ONCOL

JF - THER ADV MED ONCOL

SN - 1758-8340

ER -